The EASYXâ„¢ Liquid Embolic is a new injectable, precipitating polymeric agent for the obliteration of vascular spaces through direct puncture or catheter access performed under X-ray guidance. The embolic liquid is an iodinized Polyvinyl Alcohol (PVA) Polymer ether. Iodine groups are covalently grafted to the PVA polymer backbone, whereby a stable nondegradable polymer with the desired features is created. The resulting polymer is dissolved in Dimethyl Sulfoxide (DMSO). EASYXâ„¢ is CE-marked since December 2016 and has been used in humans a few time for type II endoleaks, portal vein and varicocele (\<10 cases at the date of submission). The purpose of this study is to evaluate the safety and efficacy of EASYXâ„¢ embolization liquid for the percutaneous treatment of vascular lesions, i.e. embolization of varicocele, type II endoleaks, portal vein before surgery, active peripheral bleeding or angiomyolipoma (AML).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety:Total number of per-procedure Serious Adverse Events (SAE) for the safety
Timeframe: one day
Efficacy for type 2 endoleaks embolization
Timeframe: 6 months
Efficacy for portal vein embolization
Timeframe: Before ablation
Efficacy for varicocele embolization
Timeframe: 1 month
Efficacy for angiomyolipoma embolization
Timeframe: 3 month
Efficacy for active bleeding embolization
Timeframe: Through embolization completion